› Forums › General Melanoma Community › Next Generation Medicines
- This topic has 33 replies, 5 voices, and was last updated 10 years ago by
rick1981.
- Post
-
- October 7, 2014 at 9:38 am
Hi everyone,
It seems like progress on cancer/melanoma treatment is moving at an incredible pace – which is a good thing. When my wife was diagnosed with Stage IV in June, our oncologist referred to Nivolumab as that "wonder medicine" he'd which he'd have access to – and only a couple of months later Pembrolizumab has been approved in the US and Expanded Access has open in Europe and Nivolumab is not far behind.
It's great to have options after the BRAF/MEK inhibitors (or in the future maybe as first line), but it thought it would be good as well to think even further out and look at what medicines may be next up in the Big Pharma's pipeline – so we can discuss this & potential trials with our oncologists.
So therefore this topic 🙂
(If it already exists, please point me in the right direction and this one can be closed).
The two melanoma medicines that have come to my attention very recently are:
BAVITUXIMAB: http://money.cnn.com/news/newsfeeds/articles/marketwire/1149321.htm. "statistically significant tumor growth suppression compared to anti-PD-1 antibody treatment alone in an animal model of melanoma". Trial with Yervoy/Ipi being started.
LIRILUMAB: http://www.mskcc.org/cancer-care/trial/12-224 Trial with Nivo. Ashley here on MPIP has mentioned this trial.
Good to know who's on these trials, what other medicines are being tested – and in the future to keep each other posted on Trial outcomes.
Best regards, Rick
- Replies
-
-
- October 7, 2014 at 3:22 pm
On the immunotherapy beat I keep hearing about IDO inhibitors and Lag-3 as showing great promise as a next gen treatment. There is also a chemo-therapy (ADC) that was getting a lot of press at one point–informed by genetics it delivers the cytotoxin directly to the tumor. It would be nice to have an update on that. Way down the pike but high on the imaginative scale–Yale Cancer Center has successfully used a virus to attack melanoma in mice (lucky mice). I believe there are quite a number of other treatments being tested….
-
- October 7, 2014 at 3:22 pm
On the immunotherapy beat I keep hearing about IDO inhibitors and Lag-3 as showing great promise as a next gen treatment. There is also a chemo-therapy (ADC) that was getting a lot of press at one point–informed by genetics it delivers the cytotoxin directly to the tumor. It would be nice to have an update on that. Way down the pike but high on the imaginative scale–Yale Cancer Center has successfully used a virus to attack melanoma in mice (lucky mice). I believe there are quite a number of other treatments being tested….
-
- October 7, 2014 at 4:06 pm
Is ADC antibody drug conjugates? If so I got very disappointed when someone on here posted the results of their phase 2 trial. Although the results were pretty good with if I remember right it was in the 30s percent receiving clinical benefit the company cancelled it. Maybe someone will pick it up again and maybe even improve it. That was my plan B back then. Sorry I didn't keep the url to the article on it.
There's also another type of chemo with this phase 1 trial NCT02020707. One of it's chemo back in 2009 was being compared with zelboraf. This trial combines it with some others as well.
There is also TIL in a phase 2 trial and several phase 1 trials with a rumor of a big trial for it coming in 2015.
Also is WDVAX in a phase 1 trial. I have not heard anyone doing it or results but it's pre trial with mice was awesome results. Of course we don't know yet how that will translate to us humans. They are also working on a less invasive delivery system instead of surgical implants they are working on a type of gel to inject the scaffold in with and some other ideas.
Also here's an article on the various mutations that makes my head spin:
Artie
-
- October 7, 2014 at 7:03 pm
The learned people at the Melanoma Institute in Sydney are very hopeful of further developments coming on track and speak of combination treatments working in several ways as the path forward. They talk of first line combinations and second line combinations and treating peoplemore aggressively with adjuvant drugs much earlier.
I can remember HAART studies for HIV decades ago. The results were so astonishing that the trials were immediatly stopped and anti HIV drugs were fast tacked into production. I was caring for people with HIV at the time and was watching them preparefor their impending deaths. Some of them are still alive 20 years later. Some moaned that they had to find a job again because they were so well on the new combination therapies. The profits these drugs generate are probably helping to fund research into melanoma.
I may be delusional but melanoma does seem to me have the same sense of excitement amongst the few scientists I have spoken to as anti HIV drugs did. Given the time lag on trials and approvals, in three to five years it will be a different ball game,it seems to me. In HIV the problem was one of viral mutation. I may be wrong but in melanoma it seems to be the number of different genetic pathways open to cells to take to replicate is a big challenge and that is why the drugs only seem to work for a certain amount of time – but I am no scientist. I'm sure many who post know much more than I do.
I'm currently stage 3b and have been told I am considered high risk to further progression. I'm not sure how that is defined, and maybe everyone at 3b is high risk, but there you go. Statistically, I have been told I have a 48% chance of surviving 5 years. I think if I am lucky to get to five years, there just might be better combination therapies there for everyone with this diagnosis.
-
- October 30, 2014 at 5:16 pm
Hi all,
Here two new development in the field of melanoma:
So summarizing what seems to be promising are:
– Bavituximab (immuno theraphy)
– Bevacizumab/Avastin (angiogenesis inhibitor, VEGF targeter)
– Lirilumab (anti-KIR: killer-cell immunoglobulin-like receptors)
– Anti-angiogenic therapies: http://www.medicaldaily.com/scientists- … ors-307654
– PV-10 (Intralesional)Good to keep following these!
-
- October 30, 2014 at 5:16 pm
Hi all,
Here two new development in the field of melanoma:
So summarizing what seems to be promising are:
– Bavituximab (immuno theraphy)
– Bevacizumab/Avastin (angiogenesis inhibitor, VEGF targeter)
– Lirilumab (anti-KIR: killer-cell immunoglobulin-like receptors)
– Anti-angiogenic therapies: http://www.medicaldaily.com/scientists- … ors-307654
– PV-10 (Intralesional)Good to keep following these!
-
- October 30, 2014 at 5:16 pm
Hi all,
Here two new development in the field of melanoma:
So summarizing what seems to be promising are:
– Bavituximab (immuno theraphy)
– Bevacizumab/Avastin (angiogenesis inhibitor, VEGF targeter)
– Lirilumab (anti-KIR: killer-cell immunoglobulin-like receptors)
– Anti-angiogenic therapies: http://www.medicaldaily.com/scientists- … ors-307654
– PV-10 (Intralesional)Good to keep following these!
-
- October 31, 2014 at 8:44 am
Ah one surprising route I heard about the radio recently…. ALPACA immunity boosters. I'm sure you wouldn't believe me if Merck hadn't just signed a licensing deal with this Belgian/Dutch company: http://www.google.com/url?url=http://www.ft.com/cms/s/0/6b5d31fe-8bf5-11e3-bcf2-00144feab7de.html&rct=j&frm=1&q=&esrc=s&sa=U&ei=hUlTVI-THISE7gbO94HQDw&ved=0CBQQFjAA&sig2=681Eyu9x2j2bsqldkPtS_Q&usg=AFQjCNEhZnAn0RDVw-fVDC6H8VMoY6Yyqg 🙂
The explained in the show that some lab researcher by accident found that alpacas have extremely well developed immune systems. And that if you place a human cancer cell into the alpaca, the cancer cell gets destroyed while the alpaca is not harmed. If only we could have that immune system, right?! So that's what's this company is exploring….
-
- November 6, 2014 at 8:04 am
And yet one more new medicine, with positive trial results: sargramostim.
-
- November 7, 2014 at 9:15 am
And yet another piece of news on treatment options: Ipi plus Leukine
-
- November 10, 2014 at 11:39 am
Hi all,
This is what our MD had to say about 2 recent studies:
"[b]Ipilimumab plus GM-CSF (sargramostim)[/b] phase III results are controversial because although the OS improves the PFS does not. So taking into account the anti-PD1 treatments, this doesn't really make any changes to the theurapeutic strategy"
"The anti-KIR treatment plus nivolumab is promising but still in phase 1 research. The anti-VEGF seems to improve the impact of ipi but not that of anti-PD-L1 plus [b]Bevacizumab/Avastin[/b]"
-
- November 10, 2014 at 11:55 am
CORRECTION TO PREVIOUS POST:
Hi all,
This is what our MD had to say about 3 recent studies:
"[b]Ipilimumab plus GM-CSF (sargramostim)[/b] phase III results are controversial because although the OS improves the PFS does not. So taking into account the anti-PD1 treatments, this doesn't really make any changes to the theurapeutic strategy"
"The [b]anti-KIR treatment (Lirilumab)[/b] plus nivolumab is promising but still in phase 1 research".
"The anti-VEGF seems to improve the impact of ipi but not that of anti-PD-L1 plus [b]Bevacizumab/Avastin[/b]"
-
- November 10, 2014 at 11:55 am
CORRECTION TO PREVIOUS POST:
Hi all,
This is what our MD had to say about 3 recent studies:
"[b]Ipilimumab plus GM-CSF (sargramostim)[/b] phase III results are controversial because although the OS improves the PFS does not. So taking into account the anti-PD1 treatments, this doesn't really make any changes to the theurapeutic strategy"
"The [b]anti-KIR treatment (Lirilumab)[/b] plus nivolumab is promising but still in phase 1 research".
"The anti-VEGF seems to improve the impact of ipi but not that of anti-PD-L1 plus [b]Bevacizumab/Avastin[/b]"
-
- November 10, 2014 at 11:55 am
CORRECTION TO PREVIOUS POST:
Hi all,
This is what our MD had to say about 3 recent studies:
"[b]Ipilimumab plus GM-CSF (sargramostim)[/b] phase III results are controversial because although the OS improves the PFS does not. So taking into account the anti-PD1 treatments, this doesn't really make any changes to the theurapeutic strategy"
"The [b]anti-KIR treatment (Lirilumab)[/b] plus nivolumab is promising but still in phase 1 research".
"The anti-VEGF seems to improve the impact of ipi but not that of anti-PD-L1 plus [b]Bevacizumab/Avastin[/b]"
-
- November 14, 2014 at 9:17 am
http://www.coloradocancerblogs.org/next-gen-melanoma-drug-tak-733-excels-lab-tests/
Promising early results on 2nd generation BRAF/MEK inhibitor
-
- November 14, 2014 at 9:17 am
http://www.coloradocancerblogs.org/next-gen-melanoma-drug-tak-733-excels-lab-tests/
Promising early results on 2nd generation BRAF/MEK inhibitor
-
- November 14, 2014 at 9:17 am
http://www.coloradocancerblogs.org/next-gen-melanoma-drug-tak-733-excels-lab-tests/
Promising early results on 2nd generation BRAF/MEK inhibitor
-
- November 10, 2014 at 11:39 am
Hi all,
This is what our MD had to say about 2 recent studies:
"[b]Ipilimumab plus GM-CSF (sargramostim)[/b] phase III results are controversial because although the OS improves the PFS does not. So taking into account the anti-PD1 treatments, this doesn't really make any changes to the theurapeutic strategy"
"The anti-KIR treatment plus nivolumab is promising but still in phase 1 research. The anti-VEGF seems to improve the impact of ipi but not that of anti-PD-L1 plus [b]Bevacizumab/Avastin[/b]"
-
- November 10, 2014 at 11:39 am
Hi all,
This is what our MD had to say about 2 recent studies:
"[b]Ipilimumab plus GM-CSF (sargramostim)[/b] phase III results are controversial because although the OS improves the PFS does not. So taking into account the anti-PD1 treatments, this doesn't really make any changes to the theurapeutic strategy"
"The anti-KIR treatment plus nivolumab is promising but still in phase 1 research. The anti-VEGF seems to improve the impact of ipi but not that of anti-PD-L1 plus [b]Bevacizumab/Avastin[/b]"
-
- November 7, 2014 at 9:15 am
And yet another piece of news on treatment options: Ipi plus Leukine
-
- November 7, 2014 at 9:15 am
And yet another piece of news on treatment options: Ipi plus Leukine
-
- November 6, 2014 at 8:04 am
And yet one more new medicine, with positive trial results: sargramostim.
-
- November 6, 2014 at 8:04 am
And yet one more new medicine, with positive trial results: sargramostim.
-
- October 31, 2014 at 8:44 am
Ah one surprising route I heard about the radio recently…. ALPACA immunity boosters. I'm sure you wouldn't believe me if Merck hadn't just signed a licensing deal with this Belgian/Dutch company: http://www.google.com/url?url=http://www.ft.com/cms/s/0/6b5d31fe-8bf5-11e3-bcf2-00144feab7de.html&rct=j&frm=1&q=&esrc=s&sa=U&ei=hUlTVI-THISE7gbO94HQDw&ved=0CBQQFjAA&sig2=681Eyu9x2j2bsqldkPtS_Q&usg=AFQjCNEhZnAn0RDVw-fVDC6H8VMoY6Yyqg 🙂
The explained in the show that some lab researcher by accident found that alpacas have extremely well developed immune systems. And that if you place a human cancer cell into the alpaca, the cancer cell gets destroyed while the alpaca is not harmed. If only we could have that immune system, right?! So that's what's this company is exploring….
-
- October 31, 2014 at 8:44 am
Ah one surprising route I heard about the radio recently…. ALPACA immunity boosters. I'm sure you wouldn't believe me if Merck hadn't just signed a licensing deal with this Belgian/Dutch company: http://www.google.com/url?url=http://www.ft.com/cms/s/0/6b5d31fe-8bf5-11e3-bcf2-00144feab7de.html&rct=j&frm=1&q=&esrc=s&sa=U&ei=hUlTVI-THISE7gbO94HQDw&ved=0CBQQFjAA&sig2=681Eyu9x2j2bsqldkPtS_Q&usg=AFQjCNEhZnAn0RDVw-fVDC6H8VMoY6Yyqg 🙂
The explained in the show that some lab researcher by accident found that alpacas have extremely well developed immune systems. And that if you place a human cancer cell into the alpaca, the cancer cell gets destroyed while the alpaca is not harmed. If only we could have that immune system, right?! So that's what's this company is exploring….
-
- October 7, 2014 at 7:03 pm
The learned people at the Melanoma Institute in Sydney are very hopeful of further developments coming on track and speak of combination treatments working in several ways as the path forward. They talk of first line combinations and second line combinations and treating peoplemore aggressively with adjuvant drugs much earlier.
I can remember HAART studies for HIV decades ago. The results were so astonishing that the trials were immediatly stopped and anti HIV drugs were fast tacked into production. I was caring for people with HIV at the time and was watching them preparefor their impending deaths. Some of them are still alive 20 years later. Some moaned that they had to find a job again because they were so well on the new combination therapies. The profits these drugs generate are probably helping to fund research into melanoma.
I may be delusional but melanoma does seem to me have the same sense of excitement amongst the few scientists I have spoken to as anti HIV drugs did. Given the time lag on trials and approvals, in three to five years it will be a different ball game,it seems to me. In HIV the problem was one of viral mutation. I may be wrong but in melanoma it seems to be the number of different genetic pathways open to cells to take to replicate is a big challenge and that is why the drugs only seem to work for a certain amount of time – but I am no scientist. I'm sure many who post know much more than I do.
I'm currently stage 3b and have been told I am considered high risk to further progression. I'm not sure how that is defined, and maybe everyone at 3b is high risk, but there you go. Statistically, I have been told I have a 48% chance of surviving 5 years. I think if I am lucky to get to five years, there just might be better combination therapies there for everyone with this diagnosis.
-
- October 7, 2014 at 7:03 pm
The learned people at the Melanoma Institute in Sydney are very hopeful of further developments coming on track and speak of combination treatments working in several ways as the path forward. They talk of first line combinations and second line combinations and treating peoplemore aggressively with adjuvant drugs much earlier.
I can remember HAART studies for HIV decades ago. The results were so astonishing that the trials were immediatly stopped and anti HIV drugs were fast tacked into production. I was caring for people with HIV at the time and was watching them preparefor their impending deaths. Some of them are still alive 20 years later. Some moaned that they had to find a job again because they were so well on the new combination therapies. The profits these drugs generate are probably helping to fund research into melanoma.
I may be delusional but melanoma does seem to me have the same sense of excitement amongst the few scientists I have spoken to as anti HIV drugs did. Given the time lag on trials and approvals, in three to five years it will be a different ball game,it seems to me. In HIV the problem was one of viral mutation. I may be wrong but in melanoma it seems to be the number of different genetic pathways open to cells to take to replicate is a big challenge and that is why the drugs only seem to work for a certain amount of time – but I am no scientist. I'm sure many who post know much more than I do.
I'm currently stage 3b and have been told I am considered high risk to further progression. I'm not sure how that is defined, and maybe everyone at 3b is high risk, but there you go. Statistically, I have been told I have a 48% chance of surviving 5 years. I think if I am lucky to get to five years, there just might be better combination therapies there for everyone with this diagnosis.
-
- October 7, 2014 at 4:06 pm
Is ADC antibody drug conjugates? If so I got very disappointed when someone on here posted the results of their phase 2 trial. Although the results were pretty good with if I remember right it was in the 30s percent receiving clinical benefit the company cancelled it. Maybe someone will pick it up again and maybe even improve it. That was my plan B back then. Sorry I didn't keep the url to the article on it.
There's also another type of chemo with this phase 1 trial NCT02020707. One of it's chemo back in 2009 was being compared with zelboraf. This trial combines it with some others as well.
There is also TIL in a phase 2 trial and several phase 1 trials with a rumor of a big trial for it coming in 2015.
Also is WDVAX in a phase 1 trial. I have not heard anyone doing it or results but it's pre trial with mice was awesome results. Of course we don't know yet how that will translate to us humans. They are also working on a less invasive delivery system instead of surgical implants they are working on a type of gel to inject the scaffold in with and some other ideas.
Also here's an article on the various mutations that makes my head spin:
Artie
-
- October 7, 2014 at 4:06 pm
Is ADC antibody drug conjugates? If so I got very disappointed when someone on here posted the results of their phase 2 trial. Although the results were pretty good with if I remember right it was in the 30s percent receiving clinical benefit the company cancelled it. Maybe someone will pick it up again and maybe even improve it. That was my plan B back then. Sorry I didn't keep the url to the article on it.
There's also another type of chemo with this phase 1 trial NCT02020707. One of it's chemo back in 2009 was being compared with zelboraf. This trial combines it with some others as well.
There is also TIL in a phase 2 trial and several phase 1 trials with a rumor of a big trial for it coming in 2015.
Also is WDVAX in a phase 1 trial. I have not heard anyone doing it or results but it's pre trial with mice was awesome results. Of course we don't know yet how that will translate to us humans. They are also working on a less invasive delivery system instead of surgical implants they are working on a type of gel to inject the scaffold in with and some other ideas.
Also here's an article on the various mutations that makes my head spin:
Artie
-
- October 7, 2014 at 3:22 pm
On the immunotherapy beat I keep hearing about IDO inhibitors and Lag-3 as showing great promise as a next gen treatment. There is also a chemo-therapy (ADC) that was getting a lot of press at one point–informed by genetics it delivers the cytotoxin directly to the tumor. It would be nice to have an update on that. Way down the pike but high on the imaginative scale–Yale Cancer Center has successfully used a virus to attack melanoma in mice (lucky mice). I believe there are quite a number of other treatments being tested….
-
- You must be logged in to reply to this topic.